F-PDX
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

F-PDX Trademark

Serial Number: 79247842 • Registration: 5999056

F-PDX is a trademark filed by Public University Corporation Fukushima Medical University on July 17, 2018. The trademark is classified under Class 42 (Computer & Scientific), Class 31 (Natural Agricultural Products). The application is currently registered and active.

Owner Contact Info

Public University Corporation Fukushima Medical University (6 trademarks)

1 Hikariga-oka
Fukushima 960-1295 , JP

Entity Type: 03

Trademark Details

Filing Date

July 17, 2018

Registration Date

March 3, 2020

Published for Opposition

December 17, 2019

Goods & Services

Live laboratory animals; live animals; live animals and fishes excluding food items; live birds and insects; feed for experimental animals; animal foodstuffs

Scientific research, testing and analysis services in the field of life science, pharmaceuticals, genetics, cancer detection and treatment; pharmaceutical testing, inspection, research or development services in the fields of proteins, antibodies, microorganisms and cells; pharmaceutical testing, inspection, research or development in the fields of bacteriology, cytology, antibody technology, chemistry, immunology and gene expression system; pharmaceutical testing, inspection, research or development on cell and tissue culture; testing, inspection, research or development of drugs and biologics for the prevention and treatment of diseases in the fields of autoimmunity, inflammation, oncology, fibrosis and nerve cell degeneration; testing, research, inspection or development of cancer vaccine; pharmaceutical testing, inspection, research or development of clinical trials, drugs, and biologics for the medical treatment of cancer; testing, inspection, research or development on genes, regarding genetic mutation and expression profile, and providing information relating thereto, in the field of genetics and genetic engineering; providing information on testing, inspection or research on DNA sequence, RNA sequence or amino acid sequence of protein in the field of life science; analysis or screening of DNA, RNA or protein in the field of life science for scientific research purposes; testing, inspection or research of pharmaceuticals, chemicals, cosmetics, reagents and foods, and providing scientific advice and information on the foregoing; quality evaluation for others in the field of pharmaceuticals and clinical trials; providing quality assurance services in the field of pharmaceuticals and clinical trials; medical and scientific research in the field of medical treatments for cancers and providing consultation and information on the foregoing; testing and research in the field of biotechnology and providing consultation and information on the foregoing; testing and research in the field of genetics, and providing information on the foregoing; research and consultancy in the field of zoology; testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; research on building construction or city planning; testing or research on prevention of pollution; testing or research on electricity; testing or research on civil engineering; testing, inspection or research on agriculture, livestock or fisheries; testing the functionality of machines, research on machines and laboratory apparatus and instruments; design for others of machinery and scientific research equipment, including design for others of the structural parts comprising the foregoing machinery and equipment; providing information and advice on computer system design and use of information technology to process information in the medical field, said information and advice provided via computer; computer software design, computer programming, or maintenance of computer software; providing temporary use of on-line, non-downloadable computer programs for medical image analysis via computers; rental of computers; providing temporary use of on-line, non-downloadable computer programs on data networks for the purpose of gathering, managing and reporting on scientific data, research and analysis

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jun 17, 2026 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Jun 17, 2026 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 15, 2026 APRE
TEAS SECTION 71 & 15 RECEIVED
Mar 2, 2026 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 3, 2025 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 12, 2020 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Jul 8, 2020 XXSS
GENERIC MADRID TRANSACTION CREATED
Jul 8, 2020 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 3, 2020 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 3, 2020 R.PR
NOTIFICATION PROCESSED BY IB
Dec 20, 2019 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 17, 2019 NPUB
PUBLISHED FOR OPPOSITION
Dec 17, 2019 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 4, 2019 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 4, 2019 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 27, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 8, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 5, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 5, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 1, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 9, 2019 GNRN
NON-FINAL ACTION E-MAILED
Jul 9, 2019 GNRT
NON-FINAL ACTION WRITTEN
Jul 9, 2019 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 13, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 13, 2019 CRFA
ASSIGNED TO LIE
Jun 11, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 7, 2019 TROA
REFUSAL PROCESSED BY IB
Feb 2, 2019 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jan 16, 2019 RFCS
REFUSAL PROCESSED BY MPU
Jan 16, 2019 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 7, 2019 RFCR
NON-FINAL ACTION WRITTEN
Jan 6, 2019 CNRT
APPLICATION FILING RECEIPT MAILED
Jan 2, 2019 MAFR
ASSIGNED TO EXAMINER
Dec 29, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 29, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 20, 2018 REPR